Cerecor signs deal with Merck for potential CNS drugs

Baltimore-based biotech firm Cerecor secured exclusive global rights to develop and market compounds that inhibit catechol-O-methyltransferase from Merck & Co. Cerecor said the agents have the potential to be used as treatments for addiction, schizophrenia and other central nervous system disorders. Cerecor will review more than 2,000 drug candidates and select some for clinical development. Merck could get milestone fees and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA